CCR2 and neoplasm: This discrepancy among clinical data suggests that there may be unidentified mechanisms of the CCL2–CCR2 axis with regard to the inhibition of cancer cell activation, and the dynamics of CCL2 in sera and the tumor microenvironment may be different among various cancers.